Kiniksa Pharmaceuticals International (KNSA) Operating Leases (2019 - 2026)

Kiniksa Pharmaceuticals International's Operating Leases history runs 8 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• Quarterly Operating Leases fell 23.19% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (down 23.19% YoY) and the FY2025 annual result came in at $6.5 million, down 17.2% from the prior year.
• Operating Leases was $5.9 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $6.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $11.3 million in Q2 2023 and bottomed at $1.3 million in Q2 2022.
• A 5-year average of $6.7 million and a median of $7.2 million in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases slumped 63.49% — and 2023, when it soared 782.86%.
• Kiniksa Pharmaceuticals International's Operating Leases stood at $2.6 million in 2022, then soared by 282.16% to $10.0 million in 2023, then decreased by 21.42% to $7.9 million in 2024, then slipped by 17.2% to $6.5 million in 2025, then retreated by 10.06% to $5.9 million in 2026.
• Business Quant data shows KNSA's Operating Leases at $5.9 million in Q1 2026, $6.5 million in Q4 2025, and $7.0 million in Q3 2025.